HER2陽性進行性固形腫瘍患者におけるZN-A-1041腸溶性カプセルまたは併用の第1相試験
HER2 陽性の進行性固形腫瘍患者を対象に、ZN-A-1041 腸溶性カプセルの単剤または併用の安全性、忍容性、薬物動態、および有効性を評価する第 1 相臨床試験
This will be a Phase 1, multicenter, open-label trial to evaluate the safety, tolerability, PK and efficacy of ZN-A-1041 as a monotherapy or in combination in participants with HER2-positive advanced solid tumors with or without brain metastases.
The study will consist of three phases: Phase 1a (dose escalation with ZN-A-1041 monotherapy), Phase 1b (dose escalation with ZN-A-1041 combination therapy) and Phase 1c (dose expansion with ZN-A-1041 combination therapy).
調査の概要
状態
介入・治療
- 薬:ZN-A-1041
- 薬:ZN-A-1041 + T-DM1 3.6 mg/kg iv. for Phase 1b
- 薬:ZN-A-1041 + T-Dxd 5.4 mg/kg iv. for Phase 1b
- 薬:ZN-A-1041 + PHESGO / Herceptin plus Perjeta injection for Phase 1b
- 薬:ZN-A-1041 + T-DM1 3.6 mg/kg iv. for Phase 1c
- 薬:ZN-A-1041 + T-Dxd 5.4 mg/kg iv. for Phase 1c
- 薬:ZN-A-1041 + PHESGO / Herceptin plus Perjeta injection for Phase 1c
詳細な説明
This study is composed of three parts designed to evaluate the safety and efficacy of ZN-A-1041 in participants with HER2-positive advanced solid tumors.
Phase 1a (Monotherapy Dose Escalation): In this first phase, participants will receive ZN-A-1041 alone. The study will begin with a low dose of ZN-A-1041, which will be gradually increased in new groups of participants to find the highest dose that can be given safely. This will establish the recommended dose for further study.
Phase 1b (Combination Dose Escalation): In the second phase, the study will evaluate the safety of giving ZN-A-1041 together with established standard-of-care therapies for HER2-positive breast cancer. Participants will be enrolled into one of three combination arms to receive ZN-A-1041 with either T-DM1, T-DXd, or a pertuzumab/trastuzumab-based regimen. This phase will identify the recommended dose for these combination therapies.
Phase 1c (Combination Dose Expansion): In the final phase, additional participants will be enrolled to receive ZN-A-1041 at the recommended combination doses identified in Phase 1b. This will allow for a more thorough evaluation of the safety and preliminary efficacy of these treatment regimens.
Throughout the study, participants will undergo screening, treatment, and follow-up periods to collect comprehensive data on the safety, tolerability, pharmacokinetics, and anti-tumor activity of ZN-A-1041, both as a single agent and in combination.
研究の種類
入学 (推定)
段階
- フェーズ2
- フェーズ 1
連絡先と場所
研究場所
-
-
Arizona
-
Tucson、Arizona、アメリカ、85712
- Arizona Clinical Research Center, Inc.;Hematology Oncology Physicians - Aoa
-
-
California
-
Cerritos、California、アメリカ、90703-2684
- TOI Clinical Research
-
San Francisco、California、アメリカ、94158
- UCSF Helen Diller Family CCC
-
-
Massachusetts
-
Boston、Massachusetts、アメリカ、02215
- Dana Farber Cancer Institute
-
-
Michigan
-
Ann Arbor、Michigan、アメリカ、48109
- University of Michigan Hospital
-
Detroit、Michigan、アメリカ、48201
- Barbara Ann Karmanos Cancer Institute
-
-
North Carolina
-
Durham、North Carolina、アメリカ、27710
- Duke University School of Medicine
-
-
Texas
-
Houston、Texas、アメリカ、77030-4000
- MD Anderson Cancer Center
-
-
-
-
Lancashire
-
Manchester、Lancashire、イギリス、M20 4BX
- The Christie
-
-
Merseyside
-
Liverpool、Merseyside、イギリス、L69 3GL
- Clatterbridge Cancer Centre
-
-
-
-
Emilia-Romagna
-
Parma、Emilia-Romagna、イタリア、43126
- Istituto Romagnolo per lo Studio dei Tumori Dino Amadori - IRST S.r.l - PPDS
-
-
Lombardy
-
Bergamo、Lombardy、イタリア、24127
- Asst Papa Giovanni XXIII
-
Magnago、Lombardy、イタリア、20020
- Fondazione Policlinico Universitario A Gemelli-Rome
-
-
-
-
Victoria
-
Geelong、Victoria、オーストラリア、3220
- Geelong Hospital
-
St Albans、Victoria、オーストラリア、3021
- Sunshine Hospital
-
-
-
-
-
Barcelona、スペイン、08036
- Hospital Clinic de Barcelona
-
Barcelona、スペイン、08028
- Instituto Oncologico Dr. Rosell-Hospital Universitari Dexeus-Grupo Quironsalud
-
Jaén、スペイン、23007
- Hospital Universitario de Jaen
-
Madrid、スペイン、28040
- Hospital Clinico San Carlos
-
Madrid、スペイン、28041
- Hospital Universitario 12 de Octubre
-
Madrid、スペイン、28007
- Hospital Beata Maria Ana
-
Seville、スペイン、41009
- Hospital Universitario Virgen Macarena
-
Valencia、スペイン、46010
- Hospital Clinico Universitario de Valencia
-
Valencia、スペイン、46009
- Fundacion Instituto Valenciano de Oncologia (IVO)
-
-
Barcelona
-
Argentona、Barcelona、スペイン、08310
- Instituto de Investigacion Oncologica Vall dHebron (VHIO) - EPON
-
-
LA Coruna
-
Santiago de Compostela、LA Coruna、スペイン、15706
- Hospital Clinico Universitario de Santiago
-
-
Orense
-
A Gudiña、Orense、スペイン、32540
- Hospital Universitario Ramon y Cajal
-
-
Sevilla
-
Las Cabezas de San Juan、Sevilla、スペイン、41730
- Hospital Universitario Virgen del Rocio
-
-
-
-
-
Auckland、ニュージーランド、1023
- Auckland City Hospital
-
-
-
-
-
Dijon、フランス、21000
- Centre Georges Francois Leclerc
-
Lille、フランス、59020
- Centre Oscar Lambret
-
Lyon、フランス、69373
- Centre Léon Bérard Centre Régional de Lutte Contre Le Cancer Rhône Alpes
-
Marseille、フランス、13009
- Institut Paoli-Calmettes
-
Saint-Herblain、フランス、44805
- Institut de Cancerologie de l Ouest
-
Villejuif、フランス、94800
- Gustave Roussy
-
-
Haute-Garonne
-
Toulouse、Haute-Garonne、フランス、31059
- EDOG - Institut Claudius Regaud - PPDS
-
-
参加基準
適格基準
就学可能な年齢
健康ボランティアの受け入れ
受講資格のある性別
説明
Inclusion Criteria:
- Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1
- Life expectancy of at least 6 months, as determined by the investigator
- Histologically or cytologically confirmed with unresectable or metastatic HER2-positive advanced solid tumors
- Must be relapsed or refractory after prior treatment for metastatic disease that included a taxane and trastuzumab or must have received first-line induction therapy for advanced disease a pertuzumab plus trastuzumab-based regimen or a T-DXd-based regimen
- Participants with new, untreated, progressive, or stable brain metastases are eligible
Exclusion Criteria:
- Participation in any other clinical study involving an investigational drug or device within 4 weeks prior to the first dose of study treatment
- Any intracranial lesion (brain metastasis) that requires immediate local therapy, such as surgery or radiation, or systemic corticosteroids at the time of enrollment
研究計画
研究はどのように設計されていますか?
デザインの詳細
- 主な目的:処理
- 割り当て:非ランダム化
- 介入モデル:順次割り当て
- マスキング:なし(オープンラベル)
武器と介入
参加者グループ / アーム |
介入・治療 |
|---|---|
|
実験的:1a: ZN-A-1041
Phase 1a: Participants will receive escalating doses of ZN-A-1041 orally twice a day (BID) at pre-defined dosing regimens to determine the maximum tolerated dose (MTD). |
ZN-A-1041: escalating doses orally BID at pre-defined dosing regimens to determine the MTD
他の名前:
|
|
実験的:1b: ZN-A-1041 + T-DM1 3.6 mg/kg iv.
Phase 1b Arm1:
|
ZN-A-1041: BID via oral administration T-DM1: 3.6 mg/kg given as an intravenous infusion on the first day of each treatment cycle, once every 3 weeks (21-day cycle)
他の名前:
|
|
実験的:1b: ZN-A-1041 + T-Dxd 5.4 mg/kg iv.
Phase 1b Arm2:
|
ZN-A-1041: BID via oral administration T-DXd: 5.4 mg/kg given as an intravenous infusion on the first day of each treatment cycle, once every 3 weeks (21-day cycle)
他の名前:
|
|
実験的:1b: ZN-A-1041 + PHESGO / Herceptin plus Perjeta
Phase 1b Arm3:
|
ZN-A-1041: BID via oral administration PHESGO dose is 600 mg pertuzumab/600 mg trastuzumab/2000 unites hyaluronidase every 3 weeks for subcutaneous administrations (21-day cycle) Perjeta is 420 mg administered as an intravenous infusion Herceptin is 6 mg/kg administered as an intravenous infusion
他の名前:
|
|
実験的:1c: ZN-A-1041 + T-DM1 3.6 mg/kg iv.
Phase 1c Arm1: The recommended dose combination for Phase 1c will be determined by the Investigator and the Sponsor based on the data from Phase 1b. |
ZN-A-1041: BID via oral administration T-DM1: intravenous infusion on the first day of each treatment cycle, once every 3 weeks (21-day cycle)
他の名前:
|
|
実験的:1c: ZN-A-1041 + T-Dxd 5.4 mg/kg iv.
Phase 1c Arm2: The recommended dose combination for Phase 1c will be determined by the Investigator and the Sponsor based on the data from Phase 1b. |
ZN-A-1041: BID via oral administration T-DXd: intravenous infusion on the first day of each treatment cycle, once every 3 weeks (21-day cycle)
他の名前:
|
|
実験的:1c: ZN-A-1041 + Herceptin plus Perjeta/PHESGO
Phase 1c Arm3: The recommended dose combination for Phase 1c will be determined by the Investigator and the Sponsor based on the data from Phase 1b. |
ZN-A-1041: BID via oral administration PHESGO: every 3 weeks for subcutaneous administrations (21-day cycle) Perjeta: intravenous infusion Herceptin: intravenous infusion
他の名前:
|
この研究は何を測定していますか?
主要な結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
The Incidence of Treatment-emergent Adverse Events of ZN-A-1041 as a Monotherapy in Phase 1a
時間枠:23 days
|
Dose at which no more than one out of six participant at the same dose level experiences a probable drug-related DLT. |
23 days
|
|
The Incidence of Treatment-emergent Adverse Events of ZN-A-1041 in Combination with T-DM1 or with T-DXd, or in Combination with PHESGO or Herceptin plus Perjeta
時間枠:21 days
|
Dose at which no more than one out of six participant at the same dose level experiences a probable drug-related DLT. |
21 days
|
|
RP2D
時間枠:Through study completion, an average of 1 year
|
To evaluate the safety of ZN-A-1041 in combination with T-DM1 or with T-DXd, or in combination with PHESGO or Herceptin plus Perjeta in participants on the RP2D. |
Through study completion, an average of 1 year
|
二次結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Plasma, Urine and Potentially Cerebrospinal Fluid (CSF) Level of ZN-A-1041 and its Main Metabolites
時間枠:From baseline to cycle 9 (each cycel is 21 days)
|
To assess the PK of ZN-A-1041 and its major metabolites. |
From baseline to cycle 9 (each cycel is 21 days)
|
|
Serum Level of Combination Drugs in Phase 1c
時間枠:Through study completion, an average of 2 year
|
To assess the serum concentration of combination drugs. |
Through study completion, an average of 2 year
|
|
Anti-drug Antibodies (ADAs) Evaluation in Phase 1c
時間枠:Through study completion, an average of 2 year
|
To assess the incidence of ADAs. |
Through study completion, an average of 2 year
|
|
Overall Response Rate (ORR)
時間枠:Through study completion, an average of 2 year
|
The preliminary efficacy of ZN-A-1041 as a monotherapy or combination in Phase 1a, Phase 1b and 1c. |
Through study completion, an average of 2 year
|
|
Progression Free Survival (PFS)
時間枠:Through study completion, an average of 2 year
|
The preliminary efficacy of ZN-A-1041 as a monotherapy or combination in Phase 1a, Phase 1b and 1c. |
Through study completion, an average of 2 year
|
協力者と研究者
スポンサー
捜査官
- スタディディレクター:Clinical Trials、Hoffmann-La Roche
研究記録日
主要日程の研究
研究開始 (実際)
一次修了 (推定)
研究の完了 (推定)
試験登録日
最初に提出
QC基準を満たした最初の提出物
最初の投稿 (実際)
学習記録の更新
投稿された最後の更新 (実際)
QC基準を満たした最後の更新が送信されました
最終確認日
詳しくは
本研究に関する用語
追加の関連 MeSH 用語
その他の研究ID番号
- XO45189
- ZN-A-1041-101-US (その他の識別子:Suzhou Zanrong Pharma Limited)
- 2023-508459-37-00 (Ctis)
個々の参加者データ (IPD) の計画
個々の参加者データ (IPD) を共有する予定はありますか?
IPD プランの説明
For eligible studies, qualified researchers may request access to individual patient level clinical data. See Roche's commitment to transparency of clinical study information here: https://go.roche.com/data_sharing
医薬品およびデバイス情報、研究文書
米国FDA規制医薬品の研究
米国FDA規制機器製品の研究
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。